[Skip to the reading](/contact#reading)

[Peptide Therapy News](/)

[Regulatory](/regulatory) [Research](/research)

[Archive](/#event-index) [About](/about)

Source review through 27 October 2026 · Event dates appear with reports

[Home](/) / Contact

# Where to take your question

Peptide Therapy News gives no medical advice and sells nothing. A question about an FDA date needs a different answer from a question about your health.

## There’s no inbox or contact form

This site lists no public email address and has no submission form. There’s no account to open or appointment to book, and no way to submit a medical history, test results or a message about symptoms. There isn’t a clinical service behind these pages.

The reports are there to help with reading the news. They can explain what a study found or why a regulatory date matters. They can’t tell whether a medicine is right for a particular person. That needs a conversation with a clinician who can assess the person’s health.

## For a date, finding or document

Open the source link beside the claim you want to check. It takes you to the FDA record, agency announcement or research paper supporting it. The [references page](/references) collects the same sources and explains what each adds. It’s a useful place to pick up the trail.

Look at the date as well as the headline. An older announcement tells you what happened then; it may say nothing about later developments. The reports label event dates and source dates separately. For example, an updated FDA table may not tell you when every entry changed.

## For a question about your own care

Symptoms, side effects, medicine choices and prescription questions belong with a qualified health professional. A licensed U.S. clinician can assess individual circumstances, in person or through a lawful telehealth service that can prescribe. This publication doesn’t arrange those visits or receive personal health information.

The [FDA’s safety page on unapproved medicines](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) explains concerns about compounded semaglutide and other products. Compounded medicines are not FDA-approved. Reading a trial result doesn’t establish that a drug is approved, available on prescription or right for you. Those are separate questions from whether a study reported a benefit.

## Finding the next useful page

For an announcement date, use the [event index](/#event-index). For an explanation of the date labels, see [About](/about). Within each report, the what-it-means section explains the finding’s limits beside the result. The source links let you read further without hunting through every page.

A document can settle what an announcement said. It can’t settle a personal treatment decision. Peptide Therapy News helps with the first task; a qualified clinician can help with the second. Current prescribing information also matters when discussing a medicine, even when an older news report is accurate.

## On this page

- [There’s no inbox or contact form](/contact#reader-contact)

- [For a date, finding or document](/contact#source-questions)

- [For a question about your own care](/contact#personal-care)

- [Finding the next useful page](/contact#readers-next-page)

Source review 27 October 2026

[Open the source desk](/references) [Follow the event dates](/#event-index)

Peptide Therapy News is a guide for reading the record, not a clinic, pharmacy or seller.

© 2026 Peptide Therapy News

[References](/references) [About](/about) [Contact](/contact) [Event index](/#event-index)